Literature DB >> 20556453

Analysis of clinical manifestations and pathology of lupus nephritis: a retrospective review of 82 cases.

Qiaoyan Guo1, Xuehong Lu, Lining Miao, Man Wu, Shan Lu, Ping Luo.   

Abstract

Lupus nephritis (LN) is a common secondary glomerular disease with diverse clinical manifestations and pathology. We retrospectively analyzed the clinical manifestations and pathology of 82 hospitalized LN patients (73 females and nine males) during February 2004 to February 2009. The mean age at disease onset of male patients was much younger than female patients (27.6 +/- 6.8 vs. 35.5 +/- 13.9). The kidney biopsy showed that more than 50% was IV-type LN. The II- and III-type LN were also common; their clinical manifestations were common in nephritic syndrome and (or) asymptomatic urinary abnormalities, whereas IV- and V-type LN usually presented nephrotic syndrome. Simultaneously, we investigated that the highest incidence rates of anemia and chronic renal failure were observed in IV- and IV + V-type LN. What was more, we found that serum creatinine level was higher; the interstitial involvement was more severe with renal biopsy. The serum creatinine level and renal interstitial lesions were positively correlated. Our study showed that the different pathologic phenotypes of LN were correlated with the specific clinical manifestations. However, the conclusion should be confirmed by large-scale prospective research.

Entities:  

Mesh:

Year:  2010        PMID: 20556453     DOI: 10.1007/s10067-010-1517-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  Defining lupus cases for clinical studies: the Boston weighted criteria for the classification of systemic lupus erythematosus.

Authors:  Karen H Costenbader; Elizabeth W Karlson; Lisa A Mandl
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

2.  CLINICAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. COMPUTER ANALYSIS OF 520 CASES.

Authors:  E L DUBOIS; D L TUFFANELLI
Journal:  JAMA       Date:  1964-10-12       Impact factor: 56.272

3.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

4.  Survival in systemic lupus erythematosus. A multivariate analysis of demographic factors.

Authors:  S Studenski; N B Allen; D S Caldwell; J R Rice; R P Polisson
Journal:  Arthritis Rheum       Date:  1987-12

Review 5.  On the progression of chronic renal disease.

Authors:  F Strutz; G A Müller
Journal:  Nephron       Date:  1995       Impact factor: 2.847

6.  Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network.

Authors:  M A Dooley; S Hogan; C Jennette; R Falk
Journal:  Kidney Int       Date:  1997-04       Impact factor: 10.612

7.  Lupus nephritis. Clinical course as related to morphologic forms and their transitions.

Authors:  D S Baldwin; M C Gluck; J Lowenstein; G R Gallo
Journal:  Am J Med       Date:  1977-01       Impact factor: 4.965

8.  Light, immunofluorescence and electron microscopy renal biopsy findings as predictors of mortality in eighty-five Spanish patients with systemic lupus erythematosus.

Authors:  F J Blanco; J De la Mata; J I López-Fernández; J J Gómez-Reino
Journal:  Br J Rheumatol       Date:  1994-03

9.  Successful treatment of class V+IV lupus nephritis with multitarget therapy.

Authors:  Hao Bao; Zhi-Hong Liu; Hong-Lang Xie; Wei-Xin Hu; Hai-Tao Zhang; Lei-Shi Li
Journal:  J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 10.121

10.  Clinicopathological study of the WHO classification in childhood lupus nephritis.

Authors:  Michael Zappitelli; Ciaran Duffy; Chantal Bernard; Rosie Scuccimarri; Karen Watanabe Duffy; Rhoda Kagan; Indra R Gupta
Journal:  Pediatr Nephrol       Date:  2004-03-12       Impact factor: 3.714

View more
  10 in total

1.  Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.

Authors:  Victoria L Wolf; Taylor L Phillips; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

Review 2.  Understanding mechanisms of hypertension in systemic lupus erythematosus.

Authors:  Erin B Taylor; Michael J Ryan
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-03-15

3.  Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus.

Authors:  Marcia Venegas-Pont; Keisa W Mathis; Radu Iliescu; William H Ray; Porter H Glover; Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-09-07       Impact factor: 3.619

Review 4.  An impaired neuroimmune pathway promotes the development of hypertension in systemic lupus erythematosus.

Authors:  Keisa W Mathis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-06-17       Impact factor: 3.619

5.  Hypertension in an experimental model of systemic lupus erythematosus occurs independently of the renal nerves.

Authors:  Keisa W Mathis; Marcia Venegas-Pont; Elizabeth R Flynn; Jan Michael Williams; Christine Maric-Bilkan; Terry M Dwyer; Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-08-07       Impact factor: 3.619

6.  Measuring eosinophiluria, urinary eosinophil cationic protein and urinary interleukin-5 in patients with Lupus Nephritis.

Authors:  Tereza Neuma Souza Brito; Maria José Vilar; José Bruno Almeida; Ana Luiza Souza Brito Faria; Sarah Dantas Viana Medeiros; Maria Carmo Cardoso Medeiros; Edna Marques Araújo Silva; Vanessa Marques Araújo Silva; Luanda Bárbara F Canário Souza; Luisa Karla P Arruda; Tatiana Xavier Costa; Geraldo Barroso Cavalcanti Junior; Antonio G Oliveira; Valéria Soraya Farias Sales
Journal:  Allergy Asthma Clin Immunol       Date:  2014-12-12       Impact factor: 3.406

7.  Urinary Albumin Levels are Independently Associated with Renal Lesion Severity in Patients with Lupus Nephritis and Little or No Proteinuria.

Authors:  Jin Ding; Zhaohui Zheng; Xueyi Li; Yuan Feng; Nan Leng; Zhenbiao Wu; Ping Zhu
Journal:  Med Sci Monit       Date:  2017-02-03

8.  Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis.

Authors:  Liliana Michelle Gomez Mendez; Matthew D Cascino; Tamiko R Katsumoto; Paul Brakeman; Paul Brunetta; David Jayne; Maria Dall'Era; Brad Rovin; Jay Garg
Journal:  Lupus Sci Med       Date:  2019-02-04

9.  Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus.

Authors:  Victoria L Wolf; Erin B Taylor; Michael J Ryan
Journal:  Physiol Rep       Date:  2019-05

10.  Relationship between hypoalbuminemia, hyperlipidemia and renal severity in patients with lupus nephritis: a prospective study.

Authors:  Manshu Sui; Xibei Jia; Chengyuan Yu; Xiaofang Guo; Xiaogang Liu; Ying Ji; Suhong Mu; Hongchi Wu; Rujuan Xie
Journal:  Cent Eur J Immunol       Date:  2014-06-27       Impact factor: 2.085

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.